Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to infection and asthma

Abstract

A gene related to a susceptibility of infection and asthma—the Protein-Tyrosine Phosphatase Receptor-type Delta (PTPRD) gene—a method of detecting the asthma-associated gene, a method of predicting the occurrence of asthma, a method of identifying asthma-associated alleles in PTPRD gene, a method of screening PTPRD for drugs useful in the treatment of asthma, and antibodies specific for PTPRD variants and their use in diagnostic assays.

1 . A method of determining susceptibility to asthma, said method comprising:
 a) obtaining a biological sample from a patient;   b) detecting at least one allele within the Protein-Tyrosine Phosphatase Receptor-type Delta (PTPRD) gene;   c) determining if said allele is associated with asthma, thereby indicating that the patient is susceptible to asthma.   
     
     
         2 . The method of  claim 1 , wherein said allele is selected from the single nucleotide polymorphism (SNP) at rs2279776 or rs767674. 
     
     
         3 . The method of  claim 1 , wherein said SNP is an rs2279776 loci and said loci is a C allele. 
     
     
         4 . The method of  claim 1 , wherein said SNP is an rs767674 loci and said loci is a G allele. 
     
     
         5 . The method of  claim 1 , wherein said SNP is detected by genotyping. 
     
     
         6 . The method of  claim 5 , said genotyping includes T A Q MAN ®, MC-PCR, or SN A P SHOT ™ analysis. 
     
     
         7 . A method of identifying alleles associated with susceptibility to asthma, said method comprising:
 a) obtaining biological samples from a population of patients having asthma and a population of patients not having asthma;   b) identifying at least one allele in the PTPRD gene from each biological sample; and   c) showing an association between said allele and said patients having asthma, but not with said patients not having asthma; and   d) thereby identifying said allele as associated with susceptibility to asthma.   
     
     
         8 . The method of  claim 7 , wherein said allele is selected from an SNP comprising SEQ ID NO: 1-68. 
     
     
         9 . The method of  claim 7 , wherein said allele is a polymorphism of loci rs2279776 and rs767674. 
     
     
         10 . The method of  claim 8 , wherein the identifying step comprising genotyping. 
     
     
         11 . The method of  claim 10 , the genotyping includes T AQ M AN ®, MC-PCR, or SN A P SHOT ™ analysis. 
     
     
         12 . A method of determining susceptibility to asthma, comprising obtaining a biological sample from a patient and detecting at least one allele within the PTPRD gene, wherein said allele is a C at the rs2279776 loci or a G at the rs767674 loci, thereby indicating that the patient is susceptible to asthma. 
     
     
         13 . The method of  claim 12 , wherein detecting both a C at the rs2279776 loci and a G at the rs767674 loci indicates that the patient has higher susceptible to asthma than if only a single allele is detected. 
     
     
         14 . A method of identifying an asthma treatment drug, comprising:
 a) contacting a PTPRD protein or a variant thereof with a test agent;   b) measuring the activity of PTPRD protein or variant thereof; wherein a decrease in PTPRD activity indicates that said agent is a drug for treating asthma.   
     
     
         15 . The screen of  claim 14 , wherein the variant of PTPRD is selected from the group consisting of I130M, E447Q, D1078E, or V1486D. 
     
     
         16 . An antibody for diagnosing asthma, wherein said antibody binds specifically to a PTPRD epitope selected from the group consisting of I130M, E447Q, D1078E, or V1486D.